CytoDyn(CYDY)
VANCOUVER, WA
BiotechnologyFocus: Monoclonal Antibodies
CytoDyn is a life sciences company focused on Monoclonal Antibodies.
Infectious DiseasesOncologyOncology, InflammationChemistry, Manufacturing and Control
Funding Stage
PUBLIC
Open Jobs
2
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT04313075A Compassionate Use Study of Leronlimab in Breast Cancer
N/AObservational Study of Blood Treated With Cytolin
HIV InfectionsClinical Trials (1)
NCT01048372Observational Study of Blood Treated With Cytolin
N/APRO 140
HIVClinical Trials (1)
NCT02759042An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
N/APRO 140
HIV InfectionsClinical Trials (1)
NCT00110591Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
Phase 1350 mg leronlimab
Triple Negative Breast NeoplasmsClinical Trials (1)
NCT03838367Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
Phase 1/2Placebos
Coronavirus Disease 2019Clinical Trials (1)
NCT04678830Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
Phase 2PRO 140
HIV -1 InfectionClinical Trials (1)
NCT00642707Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
Phase 2Placebo
Coronavirus Disease 2019Clinical Trials (1)
NCT04347239Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Phase 2PRO 140 350mg weekly subcutaneous
HIVClinical Trials (1)
NCT02355184An Extension of Protocol PRO 140_CD01 Study
Phase 2700mg leronlimab weekly dose
CCR5Clinical Trials (1)
NCT05730673Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
Phase 2PRO 140
HIV InfectionsClinical Trials (1)
NCT00613379PRO 140 by IV Administration in Adults With HIV-1 Infection
Phase 2PRO 140
HIVClinical Trials (1)
NCT01272258A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Phase 2Phase 2
Clinical Trials (1)
NCT04521114Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
Phase 2PRO 140
Graft Vs Host DiseaseClinical Trials (1)
NCT02737306A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation
Phase 2350 mg leronlimab
Metastatic Colorectal Cancer (mCRC)Clinical Trials (1)
NCT06699836A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
Phase 2Leronlimab
Solid Tumor, AdultClinical Trials (1)
NCT04504942Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Phase 2Placebo
Coronavirus Disease 2019Clinical Trials (1)
NCT04343651Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
Phase 2PRO 140
HIVClinical Trials (1)
NCT02175680Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
Phase 2PRO 140 350
HIV-1-infectionClinical Trials (1)
NCT05271370An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
Phase 2/3PRO 140
HIVClinical Trials (1)
NCT02859961Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
Phase 2/3Phase 2/3
Clinical Trials (1)
NCT02990858An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study
Phase 2/3PRO 140
HIVClinical Trials (1)
NCT02483078Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
Phase 2/3PRO 140
HIV-1-infectionClinical Trials (1)
NCT03902522PRO 140 in Treatment-Experienced HIV-1 Subjects
Phase 2/3Leronlimab
COVID-19 PneumoniaClinical Trials (1)
NCT04901676Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
Phase 3Leronlimab
COVID-19 PneumoniaClinical Trials (1)
NCT04901689Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
Phase 3Open Jobs (2)
Interview Prep Quick Facts
Portfolio: 25 clinical trials
SEC Filings: 2 available
Open Roles: 2 active jobs